Scientific work

Prof. Dr. Çağlayan Geredeli

121 publications. The source of the information is stated next to each publication.

Back to profile

  1. The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

    Medicina, 2026

    DOI 10.3390/medicina62010214 PMID 41597500 Open-access full textSource: OpenAlex

  2. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

    Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

    DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex

  3. Predictors of Recurrence Following Curative-Intent Local Therapy for Oligometastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study from the Turkish Oncology Group (TOG)

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612571 Source: ORCID

  4. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Open-access full textSource: OpenAlex

  5. KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

    DergiPark (Istanbul University), 2025

    Source: OpenAlex

  6. The Efficiency of Concomitant Antibiotic Usage On Survival Outcomes of Nivolumab-Treated Metastatic Renal Cell Carcinoma Patients: A Multicenter Experience

    Research Square, 2025

    DOI 10.21203/rs.3.rs-6066659/v1 Open-access full textSource: OpenAlex

  7. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

    Indian Journal of Cancer, 2024

    DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  8. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241241004 PMID 38613329 Open-access full textSource: OpenAlex

  9. The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Future Oncology, 2024

    DOI 10.1080/14796694.2024.2402212 PMID 39316555 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer

    Annali Italiani di Chirurgia, 2024

    DOI 10.62713/aic.3319 PMID 39723526 1 citation (Europe PMC) Open-access full textSource: ORCID

  11. Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience

    Oncology Research and Treatment, 2024

    DOI 10.1159/000537988 PMID 38565096 2 citations (Europe PMC) Open-access full textSource: ORCID

  12. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

    Cancers, 2024

    DOI 10.3390/cancers16223880 PMID 39594835 8 citations (Europe PMC) Open-access full textSource: ORCID

  13. The impact of body mass index on the progression free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Research Square, 2024

    DOI 10.21203/rs.3.rs-4144594/v1 Open-access full textSource: ORCID

  14. 46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102625 Open-access full textSource: OpenAlex

  15. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Open-access full textSource: OpenAlex

  16. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

    Journal of Gastrointestinal Cancer, 2023

    DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 citation (Europe PMC) Source: OpenAlex

  17. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer

    Journal of Cancer Research and Therapeutics, 2023

    DOI 10.4103/jcrt.jcrt_1657_21 PMID 37787291 2 citations (Europe PMC) Open-access full textSource: ORCID

  18. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04844-6 PMID 37184681 3 citations (Europe PMC) Open-access full textSource: ORCID

  19. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

    European Journal of Clinical Pharmacology, 2023

    DOI 10.1007/s00228-022-03435-7 PMID 36520173 20 citations (Europe PMC) Open-access full textSource: ORCID

  20. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

    Current Medical Research and Opinion, 2022

    DOI 10.1080/03007995.2022.2108619 PMID 35916475 4 citations (Europe PMC) Source: OpenAlex

  21. Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study

    Future Oncology, 2022

    DOI 10.2217/fon-2021-1248 PMID 35081732 27 citations (Europe PMC) Open-access full textSource: OpenAlex

  22. P-92 Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.04.182 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  23. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e15562 Source: OpenAlex

  24. P-90 First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.04.180 Open-access full textSource: OpenAlex

  25. Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-87391 Open-access full textSource: OpenAlex

  26. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2021-003165 PMID 35086927 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  27. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

    Research Square, 2022

    DOI 10.21203/rs.3.rs-2244330/v1 Open-access full textSource: ORCID

  28. 235P The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)

    Annals of Oncology, 2022

    DOI 10.1016/j.annonc.2022.07.274 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  29. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

    Blood, 2022

    DOI 10.1182/blood-2022-155931 1 citation (OpenAlex) Source: OpenAlex

  30. The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e13010 8 citations (OpenAlex) Source: OpenAlex

  31. Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0398 PMID 34323116 2 citations (Europe PMC) Source: OpenAlex

  32. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

    European Journal of Breast Health, 2021

    DOI 10.4274/ejbh.galenos.2020.6346 PMID 33870111 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  33. Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer

    Journal of Surgery and Medicine, 2021

    DOI 10.28982/josam.840948 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  34. P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.05.273 Open-access full textSource: OpenAlex

  35. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

    Cancer Chemotherapy and Pharmacology, 2021

    DOI 10.1007/s00280-021-04328-9 PMID 34312705 1 citation (Europe PMC) Source: OpenAlex

  36. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?

    Nuclear Medicine Communications, 2021

    DOI 10.1097/mnm.0000000000001431 PMID 33958536 7 citations (Europe PMC) Source: ORCID

  37. Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer.

    PubMed, 2020

    PMID 32277636 13 citations (Europe PMC) Source: OpenAlex

  38. The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer

    Oncology Research and Treatment, 2020

    DOI 10.1159/000508478 PMID 32570261 11 citations (Europe PMC) Source: OpenAlex

  39. Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis.

    PubMed, 2020

    PMID 33099936 10 citations (Europe PMC) Source: OpenAlex

  40. The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900944 PMID 32046577 7 citations (Europe PMC) Source: OpenAlex

  41. The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219898504 PMID 31955700 3 citations (Europe PMC) Source: OpenAlex

  42. The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

    Colorectal Disease, 2020

    DOI 10.1111/codi.15389 PMID 33002301 3 citations (Europe PMC) Source: OpenAlex

  43. Recurrence of appendix tumor: case report and literature update

    The European Research Journal, 2020

    DOI 10.18621/eurj.594013 Open-access full textSource: OpenAlex

  44. Adrenocortical Carcinoma:Single Center Experience

    Van Yüzüncü Yıl University Academic Data Management System, 2020

    Source: OpenAlex

  45. The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy

    Nutrition and Cancer, 2020

    DOI 10.1080/01635581.2020.1801774 PMID 32748654 5 citations (Europe PMC) Source: OpenAlex

  46. Evaluation of General Features of Patients with Testicular Cancer

    The Bulletin of Urooncology, 2020

    DOI 10.4274/uob.galenos.2020.1458 1 citation (OpenAlex) Open-access full textSource: ORCID

  47. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

    Journal of B.U.ON., 2020

    Source: ORCID

  48. ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer

    Medicine Science | International Medical Journal, 2020

    DOI 10.5455/medscience.2019.08.9184 Open-access full textSource: OpenAlex

  49. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer

    Oncology Research and Treatment, 2019

    DOI 10.1159/000501595 PMID 31336378 24 citations (Europe PMC) Source: OpenAlex

  50. Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population

    International Journal of Breast Cancer, 2019

    DOI 10.1155/2019/9645147 PMID 30713775 18 citations (Europe PMC) Open-access full textSource: OpenAlex